A Phase 1 Study of TJ011133 Administered Alone or in Combination with Pembrolizumab or Rituximab in Subjects with Relapsed/Refractory Advanced Solid Tumors and Lymphoma

Brief description of study

The purpose of this study is to test the safety of a study drug called TJ011133 alone, and to test the safety of TJ011133 in combination with pembrolizumab (Keytruda®) for solid tumors or rituximab (Rituxan®) for lymphoma. The study will test different dose levels to find out what effects, both good and/or bad, the study treatment has on you and your solid tumor or lymphoma. The study drug, TJ011133, is investigational and has been tested in animals, but not yet in people. This means it has not been approved for commercial use by the United States Food and Drug Administration (FDA). Keytruda® and Rituxan® are both FDA-approved. Keytruda® is approved for a variety of solid tumors. Rituxan® is approved for lymphoma and other types of blood cancers. TJ011133 is an antibody against a molecule called CD47. CD47 is found on the surface of tumor cells in the body, where it has a role in helping tumor cells hide from the body’s immune system. TJ011133 binds to CD47 on tumor cells and enables the body’s immune system to kill the tumor cells. TJ011133 may be useful in killing tumor cells on its own, or in combination with other anti-cancer therapies.

Clinical Study Identifier: s18-02083
ClinicalTrials.gov Identifier: NCT03934814

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.